Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. SPY
4. ICLR
5. JPM
6. FUL
7. LAES
8. NNE
9. IONS
10. IBM

Go back to Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1123.06 +5.80 (0.52%)
Previous Close $1117.26    52 Week High $88.16 
Open $1126.99    52 Week Low $67.88 
Day High $1133.03    P/E 259.97 
Day Low $1115.72    EPS $4.32 
Volume 217,701